Released: · Last reviewed:
Semaglutide is the first GLP-1 receptor agonist approved for clinical use. Understanding how it works requires understanding the two incretins it activates simultaneously.
Semaglutide is a once-weekly subcutaneous peptide injection. It works by selectively activating the GLP-1 (glucagon-like peptide-1) receptor — it is a single-receptor agonist, not a dual or triple agonist (tirzepatide is the dual GIP/GLP-1 agonist; semaglutide does not activate GIP). GLP-1 receptor activation produces appetite suppression via central nervous system signaling at hypothalamic appetite centers, delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression. Onset of GI effects is typically within 1-2 weeks; peak effect on weight is observed at 60-68 weeks at the maintenance 2.4 mg dose. The albumin-binding side chain modification extends the half-life to approximately 7 days, enabling weekly dosing.
NexLife is structured around clinical best practices for semaglutide. See full NexLife review.
Compounded semaglutide · clinician oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.